Hims Expands Testosterone Care with Injectable and Oral TRT, Its Largest Men’s Health Launch to Date
Business Wire•21/10/2026•08:20 ET
0
Key Highlights
- ➤Hims launches injectable and oral TRT options for eligible men
- ➤Kyzatrex oral TRT is FDA-approved and requires no injections
- ➤Testosterone was Hims’ fastest-scaling specialty outside weight loss in Q2
- ➤New offerings expand Hims’ men’s health program with three treatments
Expert Statements
Mike Chi, Chief Operating Officer at Hims & Hers
“Everything we’ve developed, from at-home testing and follow-up labs to ongoing provider support, is designed to make that relationship easier to start and sustain. With injectable and oral TRT, more men can start, and stay on track, with support at every step.”
Pete Stahl, MD, SVP of Men’s Health at Hims & Hers
“Different men need different care approaches, from encouraging the body’s own testosterone production to replacing testosterone directly. Our full set of treatment options gives our partnered clinicians more ways to deliver personalized, proactive care for testosterone deficiency to our customers.”
Hims Expands Testosterone Care with Injectable and Oral TRT, Its Largest Men’s Health Launch to Date
New injectable and oral options offer eligible men more ways to get proactive about their testosterone health
Get started
Create a free account to read the full story.